{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:34:07Z","timestamp":1778538847356,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016792"],"award-info":[{"award-number":["2016792"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2017436"],"award-info":[{"award-number":["2017436"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1173210"],"award-info":[{"award-number":["1173210"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1197177"],"award-info":[{"award-number":["1197177"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2033264"],"award-info":[{"award-number":["2033264"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196068"],"award-info":[{"award-number":["1196068"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2008501"],"award-info":[{"award-number":["2008501"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1194702"],"award-info":[{"award-number":["1194702"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["093956"],"award-info":[{"award-number":["093956"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal intolerance are associated with the daily dose administered. National Malaria Control Programmes require local information on efficacy, tolerability and safety to optimize antimalarial treatment policies for\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      malaria control and elimination efforts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A living systematic review identified efficacy studies of uncomplicated\n                      <jats:italic>P. vivax<\/jats:italic>\n                      malaria including patients treated with daily primaquine regimens, published since January 1, 2000. Available data were pooled and an R Shiny app was developed to integrate statistical analyses performed using R and Stata that assessed the impact of primaquine mg\/kg dose on efficacy, hematological safety and gastrointestinal tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of January 16, 2025, a total of 9,270 individual patient data records from 41 studies have been collated into the standardized repository. Open-access automated reports were generated for user-selected countries or regions to investigate location specific effects of primaquine dose on efficacy, safety and tolerability. The reports include visual and tabular displays of the outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These automated reports leverage a large database to provide accessible data for national and regional policy makers and researchers to assess the clinical consequences of different primaquine regimens in different endemic settings. The reports will inform local and regional policy decisions and research priorities in vivax-endemic areas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-025-05642-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:41:49Z","timestamp":1763138509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Peta","family":"Edler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megha","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishag","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam Rahim","family":"Awab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa W.","family":"Brasil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nath\u00e1lia N.","family":"Chamma-Siqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Daher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarete do Socorro M.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilia","family":"Gonzalez-Ceron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harin","family":"Karunajeewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus V. G.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ladeia-Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Ley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartini","family":"Lidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Llanos-Cuentas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhea J.","family":"Longley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Abebe","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuelton Marcelo","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brioni R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Nosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayodhia Pitaloka","family":"Pasaribu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhelio B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne Rini","family":"Poespoprodjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasithon","family":"Pukrittayakamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal Raj","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Saravu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 M.","family":"Siqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pham Vinh","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luiz F.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asnakew K.","family":"Yeshiwondim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina M.","family":"Zuluaga-Idarraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Commons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tesfay","family":"Abreha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Shafiul","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Anstey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Kevin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Hoang","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiru Shibiru","family":"Degaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Erhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo U.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endalamaw","family":"Gadisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najia","family":"Ghanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Anwar","family":"Hassanzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasif Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin C. K. W.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishikesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asrat Hailu","family":"Mekuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Nader","family":"Naadim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suaine C.","family":"Negreiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erni J.","family":"Nelwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anielle","family":"de Pina-Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jetsumon","family":"Sattabongkot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Suarez-Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fitsum G.","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle M. R.","family":"Viana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"von Seidlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"William","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Woodrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze-Ann","family":"Woon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adugna","family":"Woyessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"5642_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.pt.2020.03.009","volume":"36","author":"RN Price","year":"2020","unstructured":"Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the era of the shrinking P. falciparum map. Trends Parasitol. 2020;36:560\u201370.","journal-title":"Trends Parasitol"},{"key":"5642_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.4269\/ajtmh.20-0186","volume":"103","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis. Am J Trop Med Hyg. 2020;103:1094\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"5642_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001891","volume":"12","author":"LJ Robinson","year":"2015","unstructured":"Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. 2015;12:e1001891.","journal-title":"PLoS Med"},{"key":"5642_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003561","volume":"18","author":"CS Chu","year":"2021","unstructured":"Chu CS, White NJ. The prevention and treatment of Plasmodium vivax malaria. PLoS Med. 2021;18:e1003561.","journal-title":"PLoS Med"},{"key":"5642_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12936-017-1784-1","volume":"16","author":"K Thriemer","year":"2017","unstructured":"Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malar J. 2017;16:141.","journal-title":"Malar J"},{"key":"5642_CR6","unstructured":"WHO. Guidelines for malaria, 30 November 2024. Geneva: World Health Organization; 2024."},{"key":"5642_CR7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83433","volume":"11","author":"JA Watson","year":"2022","unstructured":"Watson JA, Commons RJ, Tarning J, Simpson JA, Llanos Cuentas A, Lacerda MVG, et al. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis. Elife. 2022;11:e83433.","journal-title":"Elife"},{"key":"5642_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","volume":"23","author":"I Sutanto","year":"2023","unstructured":"Sutanto I, Soebandrio A, Ekawati LL, Chand K, Noviyanti R, Satyagraha AW, et al. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis. 2023;23:1153\u201363.","journal-title":"Lancet Infect Dis"},{"key":"5642_CR9","unstructured":"WHO. Guidelines for malaria, 25 November 2022. Geneva: World Health Organization; 2022."},{"key":"5642_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5642_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(23)00431-0","volume":"24","author":"M Rajasekhar","year":"2024","unstructured":"Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:184\u201395.","journal-title":"Lancet Infect Dis"},{"key":"5642_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/app5.314","volume":"8","author":"VSH Ruwanpura","year":"2021","unstructured":"Ruwanpura VSH, Nowak S, Gerth-Guyette E, Theodora M, Dysoley L, Haile M, et al. Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: insights from the 2019 annual APMEN vivax working group meeting. Asia Pac Policy Stud. 2021;8:208\u201342.","journal-title":"Asia Pac Policy Stud"},{"key":"5642_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijpddr.2017.03.003","volume":"7","author":"RJ Commons","year":"2017","unstructured":"Commons RJ, Thriemer K, Humphreys G, Suay I, Sibley CH, Guerin PJ, et al. The vivax surveyor: online mapping database for Plasmodium vivax clinical trials. Int J Parasitol Drugs Drug Resist. 2017;7:181\u201390.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5642_CR14","doi-asserted-by":"crossref","unstructured":"Maguire JD, Krisin, Marwoto H, Richie TL, Fryauff DJ, Baird JK. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis. 2006;42:1067\u201372.","DOI":"10.1086\/501357"},{"key":"5642_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1086\/512677","volume":"44","author":"AR Hasugian","year":"2007","unstructured":"Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007;44:1067\u201374.","journal-title":"Clin Infect Dis"},{"key":"5642_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002861","volume":"3","author":"T Leslie","year":"2008","unstructured":"Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS ONE. 2008;3:e2861.","journal-title":"PLoS ONE"},{"key":"5642_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4269\/ajtmh.2010.09-0428","volume":"82","author":"S Pukrittayakamee","year":"2010","unstructured":"Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White NJ. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg. 2010;82:542\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5642_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.actatropica.2009.10.001","volume":"113","author":"AK Yeshiwondim","year":"2010","unstructured":"Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop. 2010;113:105\u201313.","journal-title":"Acta Trop"},{"key":"5642_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1475-2875-11-404","volume":"11","author":"TM Abdallah","year":"2012","unstructured":"Abdallah TM, Ali AA, Bakri M, Gasim GI, Musa IR, Adam I. Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan. Malar J. 2012;11:404.","journal-title":"Malar J"},{"key":"5642_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/cid\/cis902","volume":"56","author":"BE Barber","year":"2013","unstructured":"Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis. 2013;56:383\u201397.","journal-title":"Clin Infect Dis"},{"key":"5642_CR21","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/infdis\/jit407","volume":"208","author":"AP Pasaribu","year":"2013","unstructured":"Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis. 2013;208:1906\u201313.","journal-title":"J Infect Dis"},{"key":"5642_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","volume":"383","author":"A Llanos-Cuentas","year":"2014","unstructured":"Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049\u201358.","journal-title":"Lancet"},{"key":"5642_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1128\/AAC.02279-12","volume":"58","author":"MM Marques","year":"2014","unstructured":"Marques MM, Costa MR, Santana Filho FS, Vieira JL, Nascimento MT, Brasil LW, et al. Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrob Agents Chemother. 2014;58:342\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"5642_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12936-015-0925-7","volume":"14","author":"S Gomes Mdo","year":"2015","unstructured":"Gomes Mdo S, Vieira JL, Machado RL, Nacher M, Stefani A, Musset L, et al. Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors. Malar J. 2015;14:402.","journal-title":"Malar J"},{"key":"5642_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12936-015-0938-2","volume":"14","author":"L Gonzalez-Ceron","year":"2015","unstructured":"Gonzalez-Ceron L, Rodriguez MH, Sandoval MA, Santillan F, Galindo-Virgen S, Betanzos AF, et al. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. Malar J. 2015;14:426.","journal-title":"Malar J"},{"key":"5642_CR26","first-page":"247","volume":"31","author":"K Lidia","year":"2015","unstructured":"Lidia K, Dwiprahasto I, Kristin E. Therapeutic effects of dihydroartemisinin piperaquine versus chloroquine for uncomplicated Vivax malaria in Kupang, East Nusa Tenggara, Indonesia. Int J Pharm Sci Rev Res. 2015;31:247\u201351.","journal-title":"Int J Pharm Sci Rev Res"},{"key":"5642_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12916-015-0535-9","volume":"13","author":"EJ Nelwan","year":"2015","unstructured":"Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med. 2015;13:294.","journal-title":"BMC Med"},{"key":"5642_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12936-015-0824-y","volume":"14","author":"K Rishikesh","year":"2015","unstructured":"Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, et al. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J. 2015;14:310.","journal-title":"Malar J"},{"key":"5642_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3347\/kjp.2016.54.6.733","volume":"54","author":"R Kumar","year":"2016","unstructured":"Kumar R, Guddattu V, Saravu K. Therapeutic assessment of primaquine for radical cure of Plasmodium vivax malaria at primary and tertiary care centres in Southwestern India. Korean J Parasitol. 2016;54:733\u201342.","journal-title":"Korean J Parasitol"},{"key":"5642_CR30","doi-asserted-by":"publisher","first-page":"7411","DOI":"10.1128\/AAC.00791-15","volume":"59","author":"PV Thanh","year":"2015","unstructured":"Thanh PV, Hong NV, Van NV, Louisa M, Baird K, Xa NX, et al. Confirmed Plasmodium vivax resistance to chloroquine in Central Vietnam. Antimicrob Agents Chemother. 2015;59:7411\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"5642_CR31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1128\/AAC.04270-14","volume":"59","author":"L Yuan","year":"2015","unstructured":"Yuan L, Wang Y, Parker DM, Gupta B, Yang Z, Liu H, et al. Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. Antimicrob Agents Chemother. 2015;59:1230\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"5642_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154015","volume":"11","author":"B Ley","year":"2016","unstructured":"Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study. PLoS ONE. 2016;11:e0154015.","journal-title":"PLoS ONE"},{"key":"5642_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.4269\/ajtmh.16-0410","volume":"95","author":"RJ Longley","year":"2016","unstructured":"Longley RJ, Sripoorote P, Chobson P, Saeseu T, Sukasem C, Phuanukoonnon S, et al. High efficacy of primaquine treatment for Plasmodium vivax in Western Thailand. Am J Trop Med Hyg. 2016;95:1086\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"5642_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s12936-016-1530-0","volume":"15","author":"D Pereira","year":"2016","unstructured":"Pereira D, Daher A, Zanini G, Maia I, Fonseca L, Pitta L, et al. Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. Malar J. 2016;15:477.","journal-title":"Malar J"},{"key":"5642_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157666","volume":"11","author":"K Saravu","year":"2016","unstructured":"Saravu K, Kumar R, Ashok H, Kundapura P, Kamath V, Kamath A, et al. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in Southwestern India. PLoS ONE. 2016;11:e0157666.","journal-title":"PLoS ONE"},{"key":"5642_CR36","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1128\/AAC.00186-16","volume":"60","author":"L Zuluaga-Idarraga","year":"2016","unstructured":"Zuluaga-Idarraga L, Blair S, Akinyi Okoth S, Udhayakumar V, Marcet PL, Escalante AA, et al. Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine-primaquine standard regimen in Turbo, Colombia. Antimicrob Agents Chemother. 2016;60:4610\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"5642_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002299","volume":"14","author":"T Abreha","year":"2017","unstructured":"Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299.","journal-title":"PLoS Med"},{"key":"5642_CR38","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.4269\/ajtmh.17-0290","volume":"97","author":"GR Awab","year":"2017","unstructured":"Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, et al. Chloroquine-primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial. Am J Trop Med Hyg. 2017;97:1782\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5642_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12936-017-2139-7","volume":"17","author":"LW Brasil","year":"2018","unstructured":"Brasil LW, Rodrigues-Soares F, Santoro AB, Almeida ACG, Kuhn A, Ramasawmy R, et al. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Malar J. 2018;17:57.","journal-title":"Malar J"},{"key":"5642_CR40","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/cid\/ciy319","volume":"67","author":"CS Chu","year":"2018","unstructured":"Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis. 2018;67:1543\u20139.","journal-title":"Clin Infect Dis"},{"key":"5642_CR41","doi-asserted-by":"crossref","unstructured":"Daher A, Pereira D, Lacerda MVG, Alexandre MAA, Nascimento CT, Alves de Lima ESJC, et al. Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. Malar J. 2018;17:45.","DOI":"10.1186\/s12936-018-2192-x"},{"key":"5642_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/cid\/ciy065","volume":"67","author":"MJ Grigg","year":"2018","unstructured":"Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al. Age-related clinical spectrum of Plasmodium knowlesi malaria and predictors of severity. Clin Infect Dis. 2018;67:350\u20139.","journal-title":"Clin Infect Dis"},{"key":"5642_CR43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12936-018-2472-5","volume":"17","author":"K Saravu","year":"2018","unstructured":"Saravu K, Tellapragada C, Kulavalli S, Xavier W, Umakanth S, Brahmarouphu G, et al. A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. Malar J. 2018;17:321.","journal-title":"Malar J"},{"key":"5642_CR44","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/cid\/ciy735","volume":"68","author":"CS Chu","year":"2019","unstructured":"Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al. Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis. 2019;68:1311\u20139.","journal-title":"Clin Infect Dis"},{"key":"5642_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12936-019-3072-8","volume":"18","author":"LWP de Sena","year":"2019","unstructured":"de Sena LWP, Mello A, Ferreira MVD, de Ataide MA, Dias RM, Vieira JLF. Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin. Malar J. 2019;18:439.","journal-title":"Malar J"},{"key":"5642_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215\u201328.","journal-title":"N Engl J Med"},{"key":"5642_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01965-18","volume":"63","author":"S Ladeia-Andrade","year":"2019","unstructured":"Ladeia-Andrade S, Menezes MJ, de Sousa TN, Silvino ACR, de Carvalho JF, Salla LC Jr., et al. Monitoring the efficacy of chloroquine-primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil. Antimicrob Agents Chemother. 2019;63:e01965\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"5642_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229\u201341.","journal-title":"N Engl J Med"},{"key":"5642_CR49","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/infdis\/jiz126","volume":"220","author":"KR Rijal","year":"2019","unstructured":"Rijal KR, Adhikari B, Ghimire P, Banjara MR, Das Thakur G, Hanboonkunupakarn B, et al. Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal. J Infect Dis. 2019;220:448\u201356.","journal-title":"J Infect Dis"},{"key":"5642_CR50","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929\u201338.","journal-title":"Lancet"},{"key":"5642_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2019.101499","volume":"36","author":"S Xu","year":"2020","unstructured":"Xu S, Zeng W, Ngassa Mbenda HG, Liu H, Chen X, Xiang Z, et al. Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: a prospective open-label efficacy trial. Travel Med Infect Dis. 2020;36:101499.","journal-title":"Travel Med Infect Dis"},{"key":"5642_CR52","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1473-3099(21)00358-3","volume":"22","author":"JR Poespoprodjo","year":"2022","unstructured":"Poespoprodjo JR, Burdam FH, Candrawati F, Ley B, Meagher N, Kenangalem E, et al. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet Infect Dis. 2022;22:367\u201376.","journal-title":"Lancet Infect Dis"},{"key":"5642_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12936-023-04562-x","volume":"22","author":"DA Mekonnen","year":"2023","unstructured":"Mekonnen DA, Abadura GS, Behaksra SW, Taffese HS, Bayissa GA, Bulto MG, et al. Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response. Malar J. 2023;22:135.","journal-title":"Malar J"},{"key":"5642_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1475-2875-10-297","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.","journal-title":"Malar J"},{"key":"5642_CR55","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1038\/s41467-019-13412-x","volume":"10","author":"AR Taylor","year":"2019","unstructured":"Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun. 2019;10:5595.","journal-title":"Nat Commun"},{"key":"5642_CR56","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1038\/s41467-024-51015-3","volume":"15","author":"SV Siegel","year":"2024","unstructured":"Siegel SV, Trimarsanto H, Amato R, Murie K, Taylor AR, Sutanto E, et al. Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites. Nat Commun. 2024;15:6757.","journal-title":"Nat Commun"},{"key":"5642_CR57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12916-019-1386-6","volume":"17","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide antimalarial resistance network systematic review and individual patient data meta-analysis. BMC Med. 2019;17:151.","journal-title":"BMC Med"},{"key":"5642_CR58","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12874-023-02022-3","volume":"23","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Commons RJ, Rajasekhar M, Degaga TS, Chand K, Chau NH, et al. The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial. BMC Med Res Methodol. 2023;23:198.","journal-title":"BMC Med Res Methodol"},{"key":"5642_CR59","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/S0140-6736(23)01553-2","volume":"402","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P. falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Lancet. 2023;402:2101\u201310.","journal-title":"Lancet"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05642-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T02:03:20Z","timestamp":1763172200000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5642"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05642-w","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shared data were obtained according to ethical approvals from the country of origin and original study and were shared in a controlled framework with specific restrictions on their use. The data are pseudonymised and unable to be linked to individuals. As such, this analysis did not require additional ethical approval according to the guidelines of the Oxford Central University Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAG and GCKWK are former employees of GSK and hold shares in GSK and AstraZeneca. GCKWK reports travel support from AstraZeneca. JKB reports institutional research funding from MMV, GSK, the Wellcome Trust, and Sanaria; participation on the US National Institute of Health Data Safety Monitoring Board; and membership of the Editorial Board of Travel Medicine and Infectious Diseases and the Guidelines Development Group for Malaria Control and Elimination, Global Malaria Program, WHO. RJC, RNP and JKB report contributions to Up-to-Date. NMA reports membership of the Writing Group for the Australian national Malaria Treatment Guidelines: Therapeutic Guidelines, 2025. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}